Abstract: Dermatological cosmetic combination treatments with high intensity focused ultrasound, dermal fillers, fat-reducing compounds, cavitation-prone fluids, and/or septa dissection are provided. A HIFU therapy system can include an imaging system, methods adapted to alter placement and position of a line focus band therapy, multiple simultaneous cosmetic ultrasound treatment zones in tissue, and dithering ultrasound beams from a transducer to alter placement and position of multiple cosmetic treatment zones in tissue. The HIFU systems can include a hand wand, removable transducer modules, and a control module. The dermal fillers can include hydroxyapatite. The fat-reducing compounds can include adipocytolytic compounds, pentacyclic triterpenoid compounds, proapoptotic compounds, compounds impairing differentiation of pre-adipocytes, and combinations thereof. The cavitation-prone fluids can include molecules dissolved in fluids, ethanol, glycerin, and ethylene glycol.

Abstract: A liquid composition for improving the facial contour and shape of the human or animal face by injection, the liquid composition comprising water and at least one of the following components A, B and C: at least one component A, which leads to an osmotic concentration in the range from 500 to 5000 mOsm in the liquid composition, at least one high viscosity component B, which leads to a viscosity of the liquid composition in the range from 10 to 1500 mPas, at least one micro-particles component C, comprising micro-particles with an average particle size not larger than 0.25 mm, preferably in the range of 0.001 mm to 0.25 mm, and optionally comprising a local anesthetic compound D.

Abstract: The present invention generally relates to the treatment of gynoid lipodystrophy, and more specifically to the use of calcium (hydroxy)phosphate particles in combination with at least one compound capable of reducing local subcutaneous fat in the treatment of gynoid lipodystrophy.

Abstract: Dermatological cosmetic combination treatments with high intensity focused ultrasound, dermal fillers, fat-reducing compounds, cavitation-prone fluids, and/or septa dissection are provided. A HIFU therapy system can include an imaging system, methods adapted to alter placement and position of a line focus band therapy, multiple simultaneous cosmetic ultrasound treatment zones in tissue, and dithering ultrasound beams from a transducer to alter placement and position of multiple cosmetic treatment zones in tissue. The HIFU systems can include a hand wand, removable transducer modules, and a control module. The dermal fillers can include hydroxyapatite. The fat-reducing compounds can include adipocytolytic compounds, pentacyclic triterpenoid compounds, proapoptotic compounds, compounds impairing differentiation of pre-adipocytes, and combinations thereof. The cavitation-prone fluids can include molecules dissolved in fluids, ethanol, glycerin, and ethylene glycol.

Abstract: The present invention generally relates to the treatment of gynoid lipodystrophy, and more specifically to the use of calcium (hydroxy)phosphate particles in combination with at least one compound capable of reducing local subcutaneous fat in the treatment of gynoid lipodystrophy.

Abstract: A liquid composition for improving the facial contour and shape of the human or animal face by injection, the liquid composition comprising water and at least one of the following components A, B and C: at least one component A, which leads to an osmotic concentration in the range from 500 to 5000 mOsm in the liquid composition, at least one high viscosity component B, which leads to a viscosity of the liquid composition in the range from 10 to 1500 mPas, at least one micro-particles component C, comprising micro-particles with an average particle size not larger than 0.25 mm, preferably in the range of 0.001 mm to 0.25 mm, and optionally comprising a local anesthetic compound D.

Abstract: Use of pegylated alcohols for the treatment of actinic keratosis.

Abstract: Use of an adamantaneamine derivative for the treatment of actinic keratosis.

Abstract: The present invention relates to the treatment of an individual afflicted with inflammatory skin diseases comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.

Abstract: An injectable composition comprising peroxisome proliferator-activated receptor-gamma for subcutaneous administration and a method for improving imperfections of the skin, wherein the injectable composition is subcutaneously administered at the area of skin imperfections comprising the steps: a) identifying an area of skin imperfections, b) administering a safe and cosmetically effective amount of the composition subcutaneously to the area of skin imperfections.

Abstract: The present invention relates to the treatment of an individual afflicted with inflammatory skin diseases comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.

Abstract: Aqueous phospholipid systems comprising at least one phospholipid, at least one bile acid and water are suitable for producing medicaments for the treatment of adipose tissue disorders and lead to regression of the pathologically proliferated adipose tissue.

Abstract: The present invention relates to the use of a bisphosphonate derivative according to general Formula I and/or a pharmaceutically acceptable salt thereof, wherein R1 and/or R2 are independently selected out of a group comprising hydrogen, hydroxyl, halogen, pseudohalogen, formyl, carboxy- and/or carbonyl derivatives, alkyl, long-chain alkyl, alkoxy, long-chain alkoxy, cycloalkyl, halogenalkyl, aryl, arylene, halogenaryl, heteroaryl, heteroarylene, heterocycloalkylene, heterocycloalkyl, halogenheteroaryl, alkenyl, halogenalkenyl, alkinyl, halogenalkinyl, keto, ketoaryl, halogenketoaryl, ketoheteroaryl, ketoalkyl, halogenketoalkyl, ketoalkenyl, halogenketoalkenyl, phosphoalkyl, phosphonate, phosphate, phosphine, phosphine oxide, phosphoryl, phosphoaryl, suiphonyl, sulphoalkyl, sulphoarenyl, sulphonate, sulphate, sulphone, amine, polyether, silylalkyl, silylalkyloxy, and wherein at appropriate residues one or more non-adjacent CH2-groups may be replaced independently from each other with —O—, —S—, —NH—, —NRo

Abstract: The present invention relates to the treatment of an individual afflicted with inflammatory skin diseases comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.

Abstract: Use of a mixture comprising at least one non-aromatic surfactant having a plurality of ether and/or ester groups and at least one carrier agent for the preparation of a formulation for the treatment of adipose tissue disease and/or condition with improved bioavailability and lipolysis behaviour.

Abstract: Use of a micro-emulsion comprising at least one surfactant having a HLB value between 5 and 15, at least one lipophilic substance, and water for the preparation of a formulation for the treatment of adipose tissue disease and/or condition with improved bioavailability and good release behaviour of active substances.

Abstract: Aqueous particulate system comprising at least one water dispersible biopolymer, at least one surfactant, and water for the preparation of a formulation for the treatment of adipose diseases and/or conditions with improved bioavailability and good retardation of the release of active substances.

Abstract: Aqueous preparations comprising at least one phospholipid or at least one bile acid and a component assisting degradation of fat such as riboflavin and water are suitable for producing medicaments for removing subcutaneous accumulations of fat and lead to regression of diet-resistant fat pads.

Abstract: Aqueous phospholipid systems comprising at least one phospholipid, at least one bile acid and water are suitable for producing medicaments for the treatment of adipose tissue disorders and lead to regression of the pathologically proliferated adipose tissue.

Abstract: The present invention discloses a pharmaceutical method comprising urea, a hydrophilic film-forming agent, water and/or a water-alcohol mixture that is suitable for the removal of abnormal keratinous material.